Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This study found that A(3)B(5) downregulates melanin production and suppresses melanoma cell growth by promoting proteasomal degradation of TRP-2.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This case report describes a patient with a NUDT15 minor variant who experienced severe myelosuppression due to azathioprine, emphasizing typical symptoms as clues to the adverse reaction.

This study identified N-acyl arylsulfonamides, particularly N-(Boc-piperidine-4-carbonyl)-benzenesulfonamides, as steroid sulfatase inhibitors with improved cellular potency compared to previous compounds.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This research paper reviews the anti-androgenic properties of the drug flutamide and its metabolite Sch 16423 but presents no new experimental results.

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This study found that flutamide-induced liver toxicity in prostate cancer patients was very rare, occurring in only 0.18% of cases with clinical manifestations, and symptoms resolved after discontinuing the drug.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This study by Moussa et al. reported that bicalutamide may help reduce minoxidil-induced hypertrichosis in women with female pattern hair loss.

This study suggests that combining the 5α-reductase inhibitor 4-MA with the antiandrogen Flutamide may improve prostate cancer therapy by additively inhibiting prostatic growth and androgen-sensitive functions in rats.

This study screened synthesized pyridinecarboxamides for antitumor properties and found that many, particularly 5c and 7a, showed moderate in vitro activity against various human tumor cell lines.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

In this randomized controlled study, topical Flutamide 1% gel, applied twice daily for eight weeks, significantly reduced papules and pustules in patients with mild to moderate acne vulgaris compared to baseline.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This preliminary study observed that topical nitrogen mustard was beneficial for only 1 out of 6 patients with extensive alopecia areata, with 4 patients not completing the trial.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This study found that a regimen combining cyproterone acetate and testosterone buciclate induced reversible azoospermia in bonnet monkeys, highlighting its potential as an effective male contraceptive.

This study observed that flutamide treatment reduced hair growth and improved acne and seborrhea in hirsute women, with increased androstenedione levels and no side effects noted.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.